Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 12,565

Document Document Title
WO/2022/167962A1
The present invention is directed to compound of formula (I) and, a pharmaceutically acceptable salt or a stereoisomer thereof that useful as MALT-1 inhibitors for the treatment of diseases or disorders dependent on MALT-1. The present i...  
WO/2022/167866A1
The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A), comprising formula (I). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, aut...  
WO/2022/166990A1
Provided in the present invention are a 2-(substituted phenoxy)aromatic formic acid FTO inhibitor, a preparation method therefor and the use thereof, and specifically disclosed are a compound represented by formula (I), and the use of a ...  
WO/2022/162447A1
The present invention generally relates to a process for preparation of chlorantraniliprole or a salt thereof. Further, the present invention relates to an improved process for preparation of intermediate of chlorantraniliprole.  
WO/2022/164239A1
A novel pyrazole-carboxamide derivative compound provided as one example of the present invention exhibits an antagonist activity specific to cannabinoid receptor 1, and thus has a technical effect of effectively preventing or treating d...  
WO/2022/164857A1
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N -oxides, and salts thereof, Wherein R1, R2, R3, A, X and Q are as defined in the disclosure. Also disclosed are compositions containing the compounds of F...  
WO/2022/165162A1
Selective inhibitors of cyclin-dependent kinases (CDKs) and methods of their therapeutic use, including treatment of viral infections, are disclosed.  
WO/2022/161418A1
The present invention relates to a compound of chemical formula (I), a preparation method therefor, and an application thereof, as well as a pharmaceutical composition comprising the compound as an active ingredient, or a pharmaceuticall...  
WO/2022/159454A1
In one aspect, the present disclosure provides compounds which inhibit bromodomain testis (BRDT). In some embodiments, the compounds inhibit bromodomain-2 of BRDT. In another aspect, the present disclosure provides a method of inhibiting...  
WO/2022/159445A1
The present disclosure is generally directed to activators of lipoprotein lipase useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I), or a pharmaceutically acceptable salt, isomer, solvat...  
WO/2022/159532A1
This disclosure relates to a molecule, N-(3-chloro-1H-pyrazol-4-yl)-2- (methylsulfonyl)propanamide (S2b) and processes to prepare S2b and N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2- (methylsulfonyl)propanamide (S3b) having pesticida...  
WO/2022/155471A1
The present disclosure relates to the finding that certain compounds that modulate the activity(ies) of Sigma receptors can be used to treating or ameliorate nonalcoholic fatty liver disease and related diseases or disorders. In certain ...  
WO/2022/147993A1
Provided are a diphenylpyrazole compound as represented by formula (I) below or an agrochemically acceptable salt thereof, which is a novel inhibitor targeting pest GSTs, has a wide range of inhibitory activity on GSTs in various pests, ...  
WO/2022/149617A1
The present invention provides a library which comprises from 1 × 102 to 1 × 108 compounds; the compounds have a structure in which a first core block (first CB), a first linker (first L) and a second core block (second CB) are covalen...  
WO/2022/147318A1
Provided are methods for the parenteral use of 3-methoxy-N-[3-(2-methylpyrazol-3-yl)-4-(2-morpholin-4-yleth oxy)phenyl]benzamide, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and the sequential use of parenteral an...  
WO/2022/144926A1
The present invention relates to amorphous form of N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan -2-yl}-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide of formula-1, having specific surface area (SSA) in the range from about ...  
WO/2022/147302A1
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...  
WO/2022/134287A1
The present invention relates to a method for preparing a carboxylic acid ester compound. Under the catalysis of nitrite, an carboxylic acid reacts with an alcohol in air so as to obtain an ester compound; and the alcohol is ethanol, pro...  
WO/2022/140520A1
Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compo...  
WO/2022/138944A1
The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the f...  
WO/2022/135442A1
The present invention provides a CDK2 inhibitor and a preparation method therefor. Specifically, the present invention provides a compound as represented by formula I or a pharmaceutically acceptable salt and tautomer thereof. Groups are...  
WO/2022/135365A1
Provided herein are novel compounds (e.g., Formula I or II), pharmaceutical compositions, and methods of using related to cyclin dependent kinases (CDKs). The compounds herein are typically CDK2 inhibitors, which can be used for treating...  
WO/2022/134297A1
The present invention relates to a preparation method for a carboxylate ester compound, comprising: under the catalysis of a nitrite ester, reacting carboxylic acid and methanol in air, so as to obtain an ester compound. The preparation ...  
WO/2022/132803A1
Provided herein are compounds, compositions, and methods for treating disorders (e.g., opioid addiction) using compounds disclosed herein, which are selective agonists of the cannabinoid 2 receptor (CB2R).  
WO/2022/129047A2
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorder...  
WO/2022/129041A1
The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurologi...  
WO/2022/131146A1
Provided is a compound having the effect of inhibiting HIF-1. In concrete terms, the present invention provides a specific nitrogen-containing heterocyclic compound.  
WO/2022/129908A1
The present invention relates to a cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof. The cannabinoid derivative of the invention is an analogue of cannabidiol (CBD). CBD is a non-psychoactive...  
WO/2022/129909A1
The present invention relates to a group of novel compounds, methods for their manufacture and the use of these compounds as research tools and as pharmaceuticals. The novel compounds are analogues of cannabidiol (CBD). CBD is a non-psyc...  
WO/2022/023496A9
The present invention relates to functionalized isonitrile compounds, formed by means of multicomponent environmentally friendly reactions, suitable for coupling to functional molecules such as biomolecules, APIs, chromophore and fluorop...  
WO/2022/122773A1
The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl) carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as R...  
WO/2022/125636A1
Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compo...  
WO/2022/056346A9
Oral dosage forms comprising eltrombopag choline, processes for preparation thereof and methods of use thereof are disclosed. The compositions disclosed exhibit enhanced bioavailability and reduced food effect compared to commercially av...  
WO/2022/118959A1
The problem addressed by the present invention is to provide a compound used in the formation of an optically anisotropic film that excels in a reverse wavelength dispersion property and a heat-and-moisture durability property, a polymer...  
WO/2022/118951A1
The present invention addresses the problem of providing: a compound to be used in forming an optically anisotropic film having excellent reverse wavelength dispersion properties; a polymerizable composition; an optically anisotropic fil...  
WO/2022/111493A1
A use of a complex of an ARB metabolite and an NEP inhibitor in the preparation of drugs for the prevention and/or treatment of nephropathy.  
WO/2022/111605A1
The present disclosure relates to an aryl or heteroaryl substituted 5-membered aromatic heterocyclic compound and the use thereof. In particular, provided is a compound as shown in formula I or a pharmaceutically acceptable salt thereof,...  
WO/2022/111694A1
The present invention relates to a quinazolinone compound, a preparation method therefor and an application thereof. The compound has a structure represented by formula (I) or formula (LI), has an excellent HPPD inhibitory effect and a s...  
WO/2022/108261A1
The present invention provides a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, and a composition for forming an organic layer.  
WO/2022/106596A1
The invention relates to a composition comprising (i) a specific pyrazole or an agriculturally acceptable salt thereof; (ii) a phosphonic acid or an agriculturally acceptable salt thereof; (iii) optionally, one or more carboxylic acids, ...  
WO/2022/100614A1
Disclosed are a benzourea ring derivative as represented by formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method therefor and the use thereof.  
WO/2022/099374A1
The present invention relates to a compound of formula (I): or a salt or solvate thereof, combinations comprising same, uses and methods thereof, and kits comprising same.  
WO/2022/100625A1
The present invention relates to novel compounds effectively antagonizing LPAR, which are a compound as shown in formula (I), or a stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug of the compound as shown in fo...  
WO/2022/096679A1
The present invention relates to compounds that modulate the conformation of Aurora Kinase A (AURKA). The compounds of the present invention are also modulators of the interactome of AURKA, and preferably alter the protein-protein intera...  
WO/2022/096450A1
The present invention relates to the use of [(1,5-diphenyl-1H-pyrazol-3-yl)oxy] acetic acid derivatives of the formula (I) and their salts (I) and compositions containing them, for reducing phytotoxic effects of agrochemicals, in particu...  
WO/2022/094244A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (I SR) and for treating related diseases, disorders, and conditions.  
WO/2022/090071A1
The present invention relates to the use of mefenpyr-diethyl for controlling phytopathogenic fungi. Further the invention relates to methods for controlling phytopathogenic fungi, wherein the fungi, their habitat, their locus, or the pla...  
WO/2022/090069A1
The present invention relates to compositions comprising mefenpyr-diethyl and a compound selected from mefentrifluconazole, metyltetraprole, benzovindiflupyr, pydiflumetofen, inpyrflux-am, isoflucypram, cyclobutrifluram, fluindapyr, pyra...  
WO/2022/089604A1
Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable ...  
WO/2022/092310A1
The present invention provides a compound, etc. which has aldehyde dehydrogenase 2 (ALDH2) activating activity. Provided are a compound represented by formula (1), a pharmaceutically acceptable salt thereof, and a prodrug thereof. [In th...  

Matches 1 - 50 out of 12,565